ClinicalTrials.gg
CompletedNCT02081534Updated Sep 14, 2020Results posted

Dose Finding Study to Treat High Phosphate Levels in the Blood.

A Phase 2 interventional study of AZD1722 and Placebo in Hyperphosphatemia, sponsored by Ardelyx. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-09-14.

Sponsored by Ardelyx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing tenapanor in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. tenapanor · Hyperphosphatemia.

Enrollment
10th of 13
162 · median 172
Started
2014
the only one that year
Phase 2
4 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
6 of 13
Ardelyx

Among the 13 studies testing tenapanor in Hyperphosphatemia, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 2, and was the 1st registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

None of the 13 studies testing tenapanor in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing tenapanor in Hyperphosphatemia as a file.
02

Study summary

Randomized. double blind, placebo controlled, parallel arms dose finding study with a 4 weeks treatment period

Read the detailed description

The study consists of a screening period of approximately 1 week, a wash out period of up to 3 weeks, where existing phosphate lowering medication is withheld, a 4-week treatment period and a follow-up period of up to 2 weeks, during which patients are put back on their pre washout phosphate lowering medication.

The wash out period will be either 1 week, 2 weeks or 3 weeks depending on the increase in s-phosphate levels.

There are 7 parallel treatment arms in the study with bid and od treatment regimens.

Laboratory efficacy endpoints and safety assessments will be evaluated at various times throughout the study.

The target population of the study is: male or female patients, above18 years of age with End Stage Renal Disease (ESRD) on chronic maintenance hemodialysis (HD) 3 times a week for a minimum of 3 months.

03

Conditions studied

  • Hyperphosphatemia

Keywords

  • S-phosphate, hyperphosphatemia, hemodialysis, ESRD
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females and males aged ≥18 years
  2. Chronic maintenance hemodialysis 3 x/week for a at least 3 months
  3. Prescribed and taking at least 3 doses of phosphate binder per day
  4. Serum phosphate levels should be between 3.5 and 8.0 mg/dL ; 1.13 mmol/L and 2.58 mmol/L (inclusive) at screening
  5. Total serum calcium levels 2.0 - 2.6 mmol/L inclusive at screening
  6. For randomization in the study, after up to 3 weeks wash out of phosphate binders, patients must have serum phosphate levels of at least 6. 0 mg/dL (1.94 mmol/L) but below 10 mg/dL (3.23 mmol/L) and have had an increase of at least 1.5 mg/dL (0.48 mmol/L) vs pre wash out

Exclusion criteria

Exclusion Criteria:

  1. Severe hyperphosphatemia defined as >10 mg/dL on Phosphate-binders at all time points during clinical routine monitoring for the 3 preceding months before screening visit.
  2. Serum parathyroid hormone >1200 pg/mL
  3. Significant metabolic acidosis
  4. Clinical signs of hypovolemia at randomization

    -

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    1 mg bid

    1 mg AZD1722 bid

    Drug: AZD1722

  • Experimental
    3 mg bid

    3 mg AZD1722 bid

    Drug: AZD1722

  • Experimental
    10 mg bid

    10 mg AZD1722 bid

    Drug: AZD1722

  • Experimental
    30 mg bid

    30 mg AZD1722 bid

    Drug: AZD1722

  • Experimental
    3 mg od

    3 mg AZD1722 od

    Drug: AZD1722

  • Experimental
    30 mg od

    30 mg AZD1722 od

    Drug: AZD1722

  • Placebo comparator
    Placebo

    Placebo (double dummy technique)

    Drug: Placebo

Interventions

  • AZD1722, oral tablet

  • DrugPlacebo

    Placebo bid, double dummy technique

06

What researchers measure

Primary outcomes

  1. Change in Serum Phosphate Levels

    Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment

    Time frame: End of wash out (pre randomization value) to end of treatment (Day 29)

Secondary outcomes

  1. Change From Baseline in Calcium x Phosphorus Product

    Change from baseline (end of wash out) in calcium x phosphorus product

    Time frame: End of wash out (pre randomization value) to end of treatment (Day 29)

07

Results

Posted Sep 14, 2020

Participant flow

Participant flow — Overall Study
Milestone1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlacebo
Started23212326222126
Completed18131913181222
Not completed58413494
Withdrew: Adverse event54310282
Withdrew: Withdrawal by subject0111101
Withdrew: Protocol violation0300001
Withdrew: Lost to follow-up0002110

Outcome measures

PrimaryChange in Serum Phosphate Levels

Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment

Time frame:
End of wash out (pre randomization value) to end of treatment (Day 29)
Reported as:
Least squares mean · mg/dL
Change in Serum Phosphate Levels
mg/dL1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlacebo
Change in Serum Phosphate Levels-.47 ± 1.553-1.18 ± 1.391-1.7 ± 2.018-1.98 ± 2.007-.56 ± 1.763-1.11 ± 1.469-.54 ± 1.802
Statistical analysis
  • 1 mg Bid vs 3 mg Bid vs 10 mg Bid vs 30 mg Bid vs 3 mg od vs 30 mg od vs Placebo · ANCOVA · p = 0.012
SecondaryChange From Baseline in Calcium x Phosphorus Product

Change from baseline (end of wash out) in calcium x phosphorus product

Time frame:
End of wash out (pre randomization value) to end of treatment (Day 29)
Reported as:
Mean · mg/dL * mg/dL
Change From Baseline in Calcium x Phosphorus Product
mg/dL * mg/dL1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlacebo
Change From Baseline in Calcium x Phosphorus Product-5.16 ± 9.75-12.02 ± 14.02-12.44 ± 15.94-16.6 ± 18.01-3.59 ± 18.59-11.02 ± 11.57-2.50 ± 13.67

Adverse events

Collected over Adverse events were collected for a total of 5 weeks; 4-weeks of treatment and 1 treatment-free week. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg Bid1/23 (4.3%)2/23 (8.7%)6/23 (26.1%)
3 mg Bid0/21 (0%)2/21 (9.5%)6/21 (28.6%)
10 mg Bid0/23 (0%)3/23 (13%)11/23 (47.8%)
30 mg Bid0/26 (0%)2/26 (7.7%)17/26 (65.4%)
3 mg od0/22 (0%)1/22 (4.5%)4/22 (18.2%)
30 mg od0/21 (0%)0/21 (0%)11/21 (52.4%)
Placebo0/26 (0%)4/26 (15.4%)3/26 (11.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
Event1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlacebo
pneumoniaInfections and infestations0/231/210/230/260/220/211/26
Head injuryInjury, poisoning and procedural complications0/231/210/230/260/220/210/26
Lacunar infarctionNervous system disorders0/230/210/230/261/220/210/26
Chest painCardiac disorders1/230/210/231/260/220/210/26
Cardiac failureCardiac disorders1/230/210/230/260/220/210/26
osteomyelitisInfections and infestations0/230/211/230/260/220/210/26
Fluid overloadMetabolism and nutrition disorders0/230/211/230/260/220/210/26
SyncopeNervous system disorders0/230/211/230/260/220/210/26
Rectal prolapseGastrointestinal disorders0/230/210/231/260/220/210/26
Deep vein thrombosisVascular disorders0/230/210/231/260/220/210/26
Most frequent other events
Most frequent other events
Event1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlacebo
DiarrheaGastrointestinal disorders6/236/2111/2317/264/2211/213/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlaceboTotal
Mean57.9 ± 14.7961.5 ± 11.2162.7 ± 12.5359.7 ± 12.9657.6 ± 15.7858.2 ± 15.7556.1 ± 13.1459.1 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlaceboTotal
Female16151517121316104
Male76891081058
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlaceboTotal
Hispanic or Latino7710486648
Not Hispanic or Latino16141322141520114
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlaceboTotal
American Indian or Alaska Native01112128
Asian10311039
Native Hawaiian or Other Pacific Islander10000001
Black or African American283963435
White17121615131617106
More than one race00000000
Unknown or Not Reported20000103
serum phosphorus
serum phosphorus(mg/dL)1 mg Bid3 mg Bid10 mg Bid30 mg Bid3 mg od30 mg odPlaceboTotal
Mean7.55 ± 1.0037.92 ± 1.0057.32 ± 1.0637.76 ± 1.1837.73 ± 1.2767.61 ± 0.8477.87 ± 1.4887.68 ± 1.124
08

Study locations

41 sites
  • Research Site
    Downey, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    Whittier, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Springfield, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Voorhees, New Jersey, United States
  • Research Site
    Flushing, New York, United States
  • Research Site
    Maspeth, New York, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Bialystok, Poland
  • Research Site
    Czestochowa, Poland
  • Research Site
    Dzialdowo, Poland
  • Research Site
    Legnica, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Radom, Poland
  • Research Site
    Szczecin, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Zamosc, Poland
  • Research Site
    Zary, Poland
  • Research Site
    Zgierz, Poland
  • Research Site
    Banska Bystrica, Slovakia
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Hlohovec, Slovakia
  • Research Site
    Kosice, Slovakia
  • Research Site
    Piestany, Slovakia
  • Research Site
    Puchov, Slovakia
  • Research Site
    Senica, Slovakia
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Doncaster, United Kingdom
  • Research Site
    Exeter, United Kingdom
  • Research Site
    Hull, United Kingdom
  • Research Site
    Leicester, United Kingdom
  • Research Site
    London, United Kingdom
09

References and documents

Publications

  • Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol Dial Transplant. 2019 Feb 1;34(2):339-346. doi: 10.1093/ndt/gfy061. PubMed 29617976 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2014
First posted
Mar 7, 2014
Start
Mar 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Sep 14, 2020
Last update
Sep 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02081534
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Mar 7, 2014
Start date
Mar 2014
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Sep 14, 2020
Last update
Sep 14, 2020

Study contacts

Geoffrey A Block, MD
principal investigator · Denver Nephrology PC, Denver, CO 80230

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion